Taste and smell dysfunction in patients more than two years after start of immune checkpoint inhibitor therapy
- Conditions
- cancermalignancy10027655
- Registration Number
- NL-OMON53895
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patient with melanoma, NSCLC or urogenital cancers >= 2 years since treatment
with at least one cycle of immune checkpoint inhibitor (CTLA-4 inhibitor,
PD-(L)1 inhibitor, or both) within the Department of Medical Oncology or
Pulmonary Oncology of the UMCG.
2. Age >=18 years at time of immune checkpoint inhibitor treatment
3. Understand or abide to the study procedures
4. Have given informed consent
A caregiver must meet all of the following criteria:
1. Age >=18 years
2. Understand or abide to the study procedures
3. Have given informed consent
1. As previous or subsequent therapies, only surgery and palliative
radiotherapy is allowed (excluding radiotherapy in the head-neck and brain
region)
2. Previous treatment in the past ten years for malignancy other than melanoma
(excluding non-melanoma skin cancer, cervical intra-epithelial neoplasia (CIN)
or carcinoma in situ of breast) (for patients: other than current malignancy)
3. History of ear-nose-throat disease or auto-immune disorder affecting taste,
smell, mouth mucosa, or saliva production (for patients: before start ICI)
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method